This finding closely reflects reports in CML patients and patient-derived immature CD34+CD38- cells that CML stem cells are spared by treatment with TKIs, including dasatinib [28, 31, 32]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.